Navigation Links
GenVec to Present at the 13th Annual BIO CEO & Investor Conference
Date:2/8/2011

GAITHERSBURG, Md., Feb. 8, 2011 /PRNewswire/ -- GenVec, Inc. (Nasdaq:  GNVC) today announced that Paul H. Fischer, Ph.D., GenVec's President and CEO, will present a company overview highlighting recent developments at the 13th Annual BIO CEO & Investor Conference on Tuesday, February 15, 2011 at 2:30 p.m. EST at the Waldorf Astoria Hotel in New York City.

A webcast of Dr. Fischer's presentation will be available both live and on replay.  To access either the live or archived webcast, log on to GenVec's website at www.genvec.com, click on "Investor Relations," and proceed to "Webcasts & Data."  The replay will be available 3 hours after the live presentation and will be accessible for 30 days.

About GenVecGenVec, Inc. is a biopharmaceutical company using superior, proprietary technology to create differentiated vaccines and therapeutics that are developed and commercialized through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the US Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss, balance disorders, and cancer; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), HSV-2, dengue fever, influenza, HIV, malaria, and foot-and-mouth disease. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.Investor and Media Contact: GenVec, Inc. Douglas J. Swirsky (240) 632-5510 dswirsky@genvec.com
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Merriman Curhan Ford Acted as Placement Agent in GenVecs $28 Million Registered Offering
2. GenVec Reports Third Quarter 2009 Financial Results
3. GenVec Announces Third Quarter 2009 Results Conference Call
4. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
5. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
6. GenVec Reports Second Quarter 2009 Financial Results
7. GenVec Expands Contract Supporting Malaria Vaccine Program
8. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
9. Lexicon Pharmaceuticals to Present at the 13th Annual BIO CEO & Investor Conference
10. Inovio Pharmaceuticals to Present at 13th Annual BIO CEO & Investor Conference
11. Mosaic to Present at Goldman Sachs Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 4, 2015 In an article published ... Center for Health Security review the clinical aspects of ... used as bioweapons. The article, "Clinical Management of Potential ... the website of the New England Journal of ... Eric Toner , and Tom Inglesby—review the clinical management ...
(Date:3/4/2015)... DUBLIN , Mar. 04, 2015 Research ... announced the addition of the "Global Biologics ... their offering. , The Global ... professional and in-depth study on the current state ... The report provides a basic overview of the ...
(Date:3/4/2015)... NEWTOWN, Pa. , March 4, 2015 ... trials services and technology provider, today announced ... and 10 countries convened at its annual ... Spain to discuss the use ... development challenges. BioClinica,s eClinical technologies include: the ...
(Date:3/4/2015)... Massachusetts , March 4, 2015 ... präsentiert innovative Entwicklungen für Diagnostik und Therapie, Strahlendosismanagement ...   Royal Philips (NYSE: ... Europäischen Röntgenkongress 2015 (ECR) bekannt, der ... stattfindet. An den Ständen Nr. 102 ...
Breaking Biology Technology:Latest Clinical Information On Bioterrorism Threats 2Global Biologics and Biosimilars Industry Report 2015-2020 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 2Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 5Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 6
... the manufacturer of,medical aesthetic lasers, announced today that ... Sanders Morris Harris Group (Nasdaq: SMHG ), ... fund expansion into,new markets., The additional funding ... channel expansion into the market of about 300,000 ...
... Sept. 19 Tengion Inc., a clinical,stage regenerative ... neo-tissues, today announced that it was one of ... innovation and,success at the 35th Anniversary Celebration of ... Partner at Quaker BioVentures -- a,venture capital investor ...
... Thirty seven medical,experts in psychiatry from across ... take urgent action to optimize services for people ... schizophrenia or bipolar,disorder(i)., Professor W. Wolfgang Fleischhacker, ... Severe Mental Disorders: Clinical,Policy, and Research Challenges which ...
Cached Biology Technology:Aerolase Retains SMH Capital Inc. to Advise on Corporate Expansion 2Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association 2Global Psychiatrists Unite to Improve Services in Mental Health 2Global Psychiatrists Unite to Improve Services in Mental Health 3
(Date:2/5/2015)... 2015 Despite a lack of advancements ... as consumer electronics, automotive, storage and telecommunication has ... (SMT) screen printers. Innovations in electronics and conversion ... the adoption curve up. Meanwhile, sale volumes of ... dispensers are indispensable in the production of complex ...
(Date:1/22/2015)... Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of ... of its new website design. "When we launched ... says Peter O,Neill , founder and CEO of FindBiometrics. ... needs involvement from the key players on a very broad ...
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... produce approximately 25 percent of the total catch by ... With such a substantial portion of the nations economy ... the Gulf of Mexico region it comes as ... scrutinized by researchers across the globe. While some recent ...
... the tanker Jessica, loaded with 150,000 gallons of fuel, struck ... one of the most precious, famous and fragile ecosystems on ... numbers of unique species of flora and fauna renowned through ... of evolution by natural selection. While scores of wildlife ...
... Mo. Craniosynostosis, the premature fusion of the skull, is ... the past several years, physicians have used two procedures to ... from ear to ear, strip back the scalp of the ... had fused. The other procedure required a small incision near ...
Cached Biology News:LSU researchers challenge analyses on sustainability of Gulf fisheries 2First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 2First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 3First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 4Craniosynostosis minimally invasive surgery holds more promise than old procedure 2
...
Sterile detoxified 10% bovine serum albumin (BSA) in Iscoves MDM. This BSA has been selected to support the optimal colony growth of human hematopoietic progenitor cells in methylcellulose-based medi...
... high-performance ICP-MS system designed for flexibility and ... II off-axis ion lens, true hyperbolic quadrupole ... handle the widest range of sample types ... now includes as standard Agilents unique ShieldTorch ...
... to the DH-2000, except that it uses a ... wavelength range and comes with a shutter (controlled ... 5 Hz) The DH-2000 Deuterium Tungsten ... deuterium and tungsten halogen light sources in a ...
Biology Products: